

Exhibit A

SEP 14 2005

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------------|
| Application Number | 10/795,819 |
| Filing Date | March 8, 2004 |
| First Named Inventor | BAKHUTASHVILI, Vladimir |
| Art Unit | 1651 |
| Examiner Name | Ruth A. Davis |
| Attorney Docket Number | 627-B-US |

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | 1 | Jean-Francois Bach, "Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases", Arthritis Res Vol. 4 (Suppl 3) pgs. S3-S15 (2002) | |
| | 2 | Nicoletti et al., "The Effects of a Nonimmunogenic Form of Murine Soluble Interferon-gamma Receptor on the Development of Autoimmune Diabetes in the NOD Mouse," Endocrinology, Vol. 137, pgs. 5567 - 5575 (1996) | |
| | 3 | Nicoletti et al., "Early Prophylaxis with Recombinant Human Interleukin-11 Prevents Spontaneous Diabetes on NOD Mice", Diabetes, Vol. 48, pgs 2333-2339 (1999) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.